Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Company Overview
Pulmonx Corp (Nasdaq: LUNG) is a commercial-stage medical technology company committed to transforming the treatment of severe lung diseases through innovative, minimally invasive therapies. Specializing in advanced interventions for chronic obstructive pulmonary disease (COPD) and emphysema, Pulmonx addresses one of the most significant unmet needs in pulmonology by offering a non-surgical alternative to the conventional lung volume reduction surgery and lung transplantation. The company is dedicated to improving patients' breathing, activity levels, and overall quality of life by reducing the detrimental effects of hyperinflated, diseased lung tissue.
Innovative Technologies and Products
Pulmonx leverages a suite of proprietary platforms and products designed to assess, analyze, and treat severe emphysema. The cornerstone of their product portfolio is the Zephyr Endobronchial Valve, a tiny, one-way valve deployed via bronchoscopy. This valve is engineered to occlude targeted segments of the lung, thereby reducing their volume and allowing healthier lung tissues to function more efficiently. Alongside the Zephyr Valve, the company provides the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which offer critical insights into lung physiology and treatment planning. These technologies work in tandem to support a comprehensive, minimally invasive treatment strategy that mitigates the risks associated with traditional surgical procedures.
Operational and Market Position
Pulmonx operates within a specialized niche of medical technology focused on interventional pulmonology. Its products are sold to hospitals and healthcare distributors across major markets including the United States, Europe, the Middle-East and Africa, and Asia Pacific. By emphasizing a non-surgical treatment option, the company appeals to both patients seeking less invasive therapies and clinicians looking for effective alternatives to high-risk surgeries. Pulmonx's solutions have secured inclusion in global treatment guidelines, underscoring their clinical relevance and validation. Through a focused commercial strategy, the company has cultivated a robust market presence, enhancing patient access to therapies that dramatically improve respiratory function and quality of life.
Clinical Evidence and Technological Excellence
Clinical studies and ongoing trials have demonstrated durable and meaningful benefits for patients treated with Pulmonx's therapies. The Zephyr Endobronchial Valve, for example, has been shown to produce significant improvements in lung function by reducing hyperinflation. The company has also presented important clinical data at leading respiratory and pulmonary conferences, highlighting the safety, effectiveness, and long-term durability of its treatment approach. This commitment to rigorous clinical evaluation not only reinforces the expertise and authoritativeness of Pulmonx but also provides healthcare professionals with the evidence needed to confidently adopt these innovative solutions.
Strategic Value Proposition
At its core, Pulmonx offers a transformative treatment paradigm that diverges from traditional surgical models by providing a minimally invasive, bronchoscopic solution for severe emphysema and COPD patients. This approach minimizes risk and recovery time while offering substantial clinical benefits. The company’s strategy is built on thorough clinical research, cutting-edge technology, and a keen understanding of the challenges faced by patients suffering from chronic lung conditions. By focusing on improving the quality of life for a traditionally underserved patient population, Pulmonx not only addresses a critical health need but also solidifies its position as a key player in the global medical technology arena.
Global Reach and Commercial Execution
With a presence in multiple regions around the globe, Pulmonx has strategically expanded its customer base through a robust network of distributors and healthcare providers. Its comprehensive commercial model ensures that its innovative products are accessible in high-demand markets, thereby driving adoption and integration into standard pulmonology practices. The company’s ongoing commitment to enhancing operational excellence, optimizing patient workflows, and expanding global outreach has been instrumental in sustaining its market momentum and shaping clinical practices across diverse healthcare settings.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025.
The company will host a conference call with management to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the earnings call through the investor relations section of Pulmonx's website.
Pulmonx (NASDAQ: LUNG) reported strong financial results for Q4 and full year 2024. The company achieved record worldwide revenue of $83.8 million for FY2024, up 22% year-over-year, and Q4 2024 revenue of $23.8 million, a 23% increase from Q4 2023.
U.S. revenue reached $56.5 million for FY2024 (23% growth) and $15.9 million for Q4 2024 (16% growth). The company maintained a gross margin of 74% throughout 2024. Net loss for FY2024 improved to $56.4 million ($1.44 per share) compared to $60.8 million ($1.60 per share) in 2023.
For 2025, Pulmonx projects revenue between $96-98 million (15-17% growth) and expects to maintain a 74% gross margin. Operating expenses are forecasted at $133-135 million, including $22 million in stock-based compensation.
Pulmonx (Nasdaq: LUNG), a pioneer in minimally invasive treatments for severe lung disease, has announced its participation in an upcoming investor event. The company will engage in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on February 27, 2025, at 8:00 AM PT / 11:00 AM ET.
Interested parties can access both live and archived versions of the presentation through the 'Investors' section of the Pulmonx website at investors.pulmonx.com.
Pulmonx (NASDAQ: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. The company will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the event through the company's investor relations website.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will engage in a fireside chat on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET in New York. Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website.
Pulmonx (Nasdaq: LUNG) and the American Lung Association are expanding their partnership with two new educational initiatives for severe COPD and emphysema patients. The programs include patient stories on the EACH BREATH blog in November 2024 featuring experiences with endobronchial valve (EBV) treatment, and an 'Ask the Expert' Q&A session with a pulmonologist in January on the Lung Association's online communities. The collaboration aims to increase awareness about Zephyr® Endobronchial Valve therapy and provide educational resources for patients and healthcare providers dealing with COPD, which remains the third leading cause of death worldwide according to WHO.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The company will engage in investor meetings at the event, which is scheduled to take place in New York on Thursday, November 21, 2024.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET in New York.
Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/.
Pulmonx (LUNG) reported Q3 2024 financial results with worldwide revenue of $20.4 million, up 15% year-over-year. U.S. revenue grew 17% to $13.8 million, while international revenue increased 12% to $6.6 million. The company maintained a gross margin of 74% and reported a net loss of $14.1 million ($0.36 per share). Operating expenses increased 3% to $29.2 million. The company added 15 new Zephyr Valve treatment centers and maintains its full-year 2024 revenue guidance of $81-84 million with expected gross margin of 74%.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced that it will release its third quarter 2024 financial results after the close of trading on Wednesday, October 30, 2024. The company management will host a conference call to discuss the financial results, starting at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Investors and interested parties can access a live and archived webcast of the event on the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
What is the core focus of Pulmonx Corp?
What are the key products offered by Pulmonx?
How does the Zephyr Endobronchial Valve work?
What makes Pulmonx's treatment approach unique?
In which markets does Pulmonx operate?
How is clinical evidence integrated into Pulmonx’s strategy?
What are the benefits of Pulmonx's treatment options for patients?
How does Pulmonx maintain its position in the competitive medical technology sector?
